Direkt zum Inhalt
Merck
Alle Fotos(2)

Dokumente

50787

Supelco

Bisoprolol

analytical standard

Synonym(e):

1-{4-{[2-(1-Methylethoxy)-ethoxy]-methyl}-phenoxy}-3-[(1-methylethyl)-amino]-2-propanol

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)

About This Item

Empirische Formel (Hill-System):
C18H31NO4
CAS-Nummer:
66722-44-9
Molekulargewicht:
325.44
MDL-Nummer:
MFCD00865795
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329757631
NACRES:
NA.24

Qualität

analytical standard

Assay

≥97.0% (HPLC)

Haltbarkeit

limited shelf life, expiry date on the label

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

Anwendung(en)

forensics and toxicology
pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CC(C)OCCOCC1=CC=C(OCC(O)CNC(C)C)C=C1

InChI

1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3

InChIKey

VHYCDWMUTMEGQY-UHFFFAOYSA-N

Angaben zum Gen

human ... ADRB1(153)

Verwandte Kategorien

Anwendung

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Piktogramme

Health hazardExclamation mark
GHS08,GHS07

Signalwort

Warning

Gefahreneinstufungen

Acute Tox. 4 Oral - Repr. 2 - STOT RE 2

Zielorgane

Heart

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number
BCCL9762
BCCK9254
BCCG9195
BCCF5130
BCCD9646

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 9

1 of 9

Nebivolol -hydrochlorid ≥98% (HPLC)

Sigma-Aldrich

N1915

Nebivolol -hydrochlorid

Atenolol ≥98% (TLC), powder

Sigma-Aldrich

A7655

Atenolol

Carvedilol ≥98% (HPLC), solid

Sigma-Aldrich

C3993

Carvedilol

Zolpidem ≥98% (HPLC), solid

Sigma-Aldrich

Z103

Zolpidem

Metoprolol -tartrat European Pharmacopoeia (EP) Reference Standard

M1830000

Metoprolol -tartrat

Nadolol analytical standard

Supelco

N1892

Nadolol

Salbutamol

Sigma-Aldrich

S8260

Salbutamol

Forskolin analytical standard

Supelco

93049

Forskolin

DL-Isoproterenol -hydrochlorid

Sigma-Aldrich

I5627

DL-Isoproterenol -hydrochlorid

Syunsuke Yamamoto et al.
Journal of pharmaceutical sciences, 106(9), 2787-2794 (2017-03-21)
Although several mathematical models have been reported for the estimation of human plasma concentration profiles of drug substances after dermal application, the successful cases that can predict human pharmacokinetic profiles are limited. Therefore, the aim of this study is to
Gyung Min Park et al.
Diabetes & metabolism journal, 44(3), 470-479 (2019-11-27)
There are limited data on the impact of diabetes control on the risk of subclinical coronary atherosclerosis. We analyzed 6,434 consecutive asymptomatic individuals without previous history of coronary artery disease who underwent coronary computed tomographic angiography (CCTA) (mean age, 53.7±7.6
Peter C Rockers et al.
The Lancet. Global health, 7(4), e492-e502 (2019-02-26)
Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first
Olivier Ghekiere et al.
The international journal of cardiovascular imaging, 35(3), 559-568 (2018-10-05)
Only one-third of intermediate-grade coronary artery stenosis (i.e. 40-70% diameter narrowing) causes myocardial ischemia, requiring most often additional invasive work-up with invasive fractional flow reserve (FFR). To evaluate the correlations between FFR estimates derived from computed tomography (FFRCT) and adenosine
Lauri Suojanen et al.
Basic & clinical pharmacology & toxicology, 121(2), 130-137 (2017-03-04)
Treatment with beta-blockers appears to show inferior reduction in central versus peripheral blood pressure. We aimed to examine simultaneous changes in central and peripheral blood pressure, vascular resistance, cardiac function and arterial stiffness during beta-blockade. Haemodynamics were investigated after 3
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.